Drug class
Antiplatelet agent; thromboxane A2 receptor antagonist and thromboxane synthase inhibitor
Mechanism of action
Inhibits platelet aggregation through antagonism of thromboxane A2 receptors and inhibition of thromboxane A2 synthesis. Clinical pharmacology studies show reduced platelet aggregation and thromboxane-related activity, although the relative contribution of the two actions varies by experimental setting.
General use cases
- Historically used for peripheral arterial disease and thrombotic vascular disorders in selected countries; current availability and authorisation are jurisdiction-specific.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
